by Dale Harrison | Oct 25, 2022 | Press Releases
Awarded patents protect novel porphyrin-conjugated compounds for selective delivery of cancer treatments SAN ANTONIO, TX – Oct. 25, 2022 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced the People’s Republic of China awarded a Certificate of Patent to...
by Dale Harrison | Oct 12, 2022 | Press Releases
Powerful platform reveals the lung environment for diagnosing lung diseases SAN ANTONIO, TX – Oct. 12, 2022 – bioAffinity Technologies, Inc., (NASDAQ: BIAF; BIAFW) will present results of its research into the use of flow cytometry for analyzing the lung environment...
by Maria Zannes | Sep 28, 2022 | Press Releases
SAN ANTONIO, TX – September 28, 2022 – bioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the...
by Dale Harrison | Sep 14, 2022 | Press Releases
SAN ANTONIO–(BUSINESS WIRE)– bioAffinity Technologies, (NASDAQ: BIAF, BIAFW), a biotechnology company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, today announced publication of its research in...
by Maria Zannes | Sep 6, 2022 | Press Releases
San Antonio, TX – September 6, 2022 – bioAffinity Technologies, Inc. (“bioAffinity” or the “Company”) (NASDAQ: BIAF, BIAFW), a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, and is researching...
by Maria Zannes | Sep 1, 2022 | Press Releases
SEPTEMBER 1, 2022(SAN ANTONIO, TX) bioAffinity Technologies, Inc., a cancer diagnostics company that develops non-invasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that...
